Planning Capital Management Corp Buys 450 Shares of BioNTech SE (NASDAQ:BNTX)

Planning Capital Management Corp boosted its stake in BioNTech SE (NASDAQ:BNTX) by 45,000.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 451 shares of the company’s stock after purchasing an additional 450 shares during the quarter. Planning Capital Management Corp’s holdings in BioNTech were worth $54,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Covestor Ltd grew its position in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares during the period. GAMMA Investing LLC raised its position in BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after purchasing an additional 238 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the period. Blue Trust Inc. increased its stake in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the period. Finally, Crewe Advisors LLC purchased a new stake in BioNTech in the first quarter worth $75,000. 15.52% of the stock is owned by institutional investors.

BioNTech Trading Down 7.1 %

BNTX stock opened at $103.56 on Friday. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market cap of $24.83 billion, a P/E ratio of -49.31 and a beta of 0.26. The company’s 50-day simple moving average is $113.34 and its 200-day simple moving average is $97.10.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the previous year, the company earned $0.73 earnings per share. The company’s quarterly revenue was up 38.9% on a year-over-year basis. As a group, equities analysts forecast that BioNTech SE will post -3.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BNTX has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a research note on Monday, November 4th. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Bank of America upped their target price on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a report on Thursday. Finally, TD Cowen decreased their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.54.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.